John Parkinson

A large study of patients treated in the intensive care unit (ICU) demonstrates common genetic links that point to a potential reason for people progressing to life-threatening forms of the respiratory virus.

An antibiotic development stakeholder believes the current paradigm needs to be changed in order for more antibiotics to get FDA approved and reduce multidrug-resistance.

This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Sulbactam-durlobactam (Xacduro) was developed to treat the troublesome Acinetobacter baumannii pathogen that can be associated with bacterial pneumonia.

The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.

Five-year cumulative data from 2 phase 3 studies looked at 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF (Biktarvy).

The National Institute for Health and Care Excellence (NICE) believes National Health Service (NHS) can use bulevirtide as a treatment option.

New therapeutics have been FDA approved as well as real-world studies glean information about their efficacy.

A vaccine developer discusses the benefits of this approach and the development behind them.

The recommendations look to increase usage of the antiviral and decrease the routine use of the recombinant IL-1 inhibitor for COVID-19 treatment.

There is a lot going on in this area in medicine and here is the most up-to-date news on health programs and therapies.

A clinician presents data on this antibiotic for these troublesome infections at the ongoing MAD-ID conference.

Sulbactam-durlobactam is efficacious against carbapenem-resistant infections, and Innoviva is preparing for the antibiotic's PDUFA at the end of this month.

The latest issue of the Morbidity and Mortality Report discusses the cases.

A new study showed an introduction of beneficial microbiota.

Ferring’s Rebyota therapeutic was studied in this population and demonstrated a 79% efficacy.

Ferring’s Rebyota, which was FDA approved late last year, demonstrated a high efficacy and favorable safety profile in the prevention of recurrent Clostridioides difficile.

The Committee for Medicinal Products for Human Use expressed a positive opinion for bulevirtide for treatment of hepatitis D (HDV).

Carlos Del Rio, MD, updates clinicians and the public on where we are now on the respiratory virus and the modalities to treat and prevent severe disease.

A clinician provides insights on this significant topic as well as resources in finding information on them.

A clinician offers some insights and considerations on clinical care as it pertains to climate.

The Gates Medical Research Institute (MRI) is collaborating with Atreca on an investigational therapy, MAM01, which is moving into clinic trials this year.

Members of both branches brought it back to gain support and passage of a bill aimed at greater development of antibiotics.

A clinician offers ideas about who to target for immunization and strategic considerations when having these conversations.

One of the most challenging aspects of clinicans’ jobs is giving patients and staff bad news. A clinician offers some strategies to help shape an approach in having these conversations.

Artificial intelligence (AI) is being utilized already says one clinician. She explains her optimism about the technology, and says it will help augment any potential challenges providers have now or in the future.

A paradigm shift is emerging when it comes to the clinical approach to prescribing antibiotics. One clinician weighs in on using this class of therapeutics more judiciously.

An epidemiologist offers some insights on what we need to take into a potential next pandemic including infrastructure investment and more effectively communicating messages to the public.

This gathering is the nation’s largest for internal medicine doctors and has many infectious disease-related scientific sessions.

The antiviral is being studied for treatment for those at high-risk for severe COVID-19, no matter their vaccine status.